ETH47

Sebastian Johnston is Professor of Respiratory Medicine & Allergy at the National Heart and Lung Institute, Imperial College London, and Honorary Consultant Physician in Respiratory Medicine & Allergy at St Mary's Hospital, Imperial Healthcare NHS Trust, London. He was Director of the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, was the Asthma UK Clinical Professor and is an NIHR Emeritus Senior Investigator. His work has led to the publishing of 10 patents, the licensing of these patents to industry and to completion of Phase I & II clinical studies on the use of IFN-beta for treatment of acute exacerbations of asthma. Prof. Johnston has extensive experience in the design and conduct of human rhinovirus challenge studies in patients with asthma and COPD.

Chris Brightling is a Fellow of the Academy of Medical Sciences, NIHR Emeritus Senior Investigator, Respiratory Theme Lead for the NIHR Leicester Biomedical Research Centre, Director of the Institute for Lung Health, Director of the Institute for Precision Health and Honorary Consultant Respiratory Physician in Leicester, UK.  His main research focuses on improving the clinical management and understanding the immunopathogenesis of Asthma, Chronic Cough, COPD and Long COVID.

Prof. William Busse is a leading pulmonologist with pioneering expertise in viral-induced asthma exacerbations and the interplay between antiviral immune responses and allergic inflammation. His landmark research has established human rhinoviruses as the predominant viral trigger of asthma attacks and elucidated deficient interferon responses in asthmatic patients. His extensive clinical research on virus-triggered asthma exacerbations in both children and adults provides critical insights into respiratory infection mechanisms in asthma.

Dave Singh is Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester, UK. He graduated in medicine from Cambridge University and then specialised in clinical pharmacology and respiratory medicine. His research interest is the development of new drugs for asthma and COPD. He is the medical director of the Medicines Evaluation Unit, an IQVIA business,  where he has acted as principal investigator in over 400 clinical trials. He is a member of the GOLD Science Committee. He was previously the chair of the European Respiratory Society airway pharmacology group. He is currently an editor of the European Respiratory Journal and European Respiratory Review. He is a fellow of the European Respiratory Society and of the British Pharmacology Society. He has over 500 publications.

Dr. Thomas Langenickel is a seasoned clinical drug development professional with more than 20 years of experience in translational medicine across multiple therapeutic areas and modalities. During his tenure as Executive Director and Head of Respiratory Profiling at Novartis AG and Medical Director at Bristol-Myers Squibb he has successfully supported clinical trial and investigational new drug applications as well as three marketing authorization applications (MAAs) / new drug applications (NDAs). Prior to his current position as Chief Medical and Development Officer at Gubra, he served as CMO at Ethris, where he advanced ETH47 from conception through early stage clinical development. Dr. Langenickel earned his M.D. from Humboldt University of Berlin and completed a postdoctoral fellowship in vascular biology at the National Heart, Lung, and Blood Institute, NIH (USA).